Schistosomiasis is blood-dwelling parasites of the genus Schistosoma, mainly S. mansoni, S.
japonicum and S. haematobium. Praziquantel® (PZQ) is the drug of choice for treatment but, its
efficacy decreased as drug resistant strains emerged due to widespread usages. This study assessed
the in-vivo anti-schistosomal effects of Tamoxifen® (TAM) compared to praziquantel on
experimental S. mansoni-infected mice regarding worm burden, liver enzymes status, cytokines
change, histopathological study and the activities of some antioxidants. Mice were infected by
~80±10 cercariae followed by a single oral dose with either praziquantel or tamoxifen 42 days
post-infection. The treated mice showed a reduction in worm burden, a decrease in egg load in
liver and intestine, a decrease in levels of AST, ALT, interferon-gamma, interleukin 4, and interleukin
10 but, with a significant activities increase of superoxide dismutase (SOD), glutathiones-
transferase (GST), glutathione peroxidase (GPx) and Catalase (CAT) and decrease in granuloma
size than infected non-treated mice